A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series

被引：24

作者：

Vaz, RJ ^{[1
]}

Nayeem, A ^{[1
]}

Santone, K ^{[1
]}

Chandrasena, G ^{[1
]}

Gavai, AV ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2005年 / 15卷 / 17期

关键词：

CYP2D6; 3D-QSAR; aryloxypropanolamines;

D O I：

10.1016/j.bmcl.2005.06.007

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A comparative molecular similarity index analysis (CoMSiA) has been performed for cytochrome P450 2D6 inhibition on a series of aryloxypropatiolamines to determine the factors contributing to this activity. The model is in agreement with a CYP2D6 homology model constructed on the basis of the mammalian CYP2C5 crystal structure. The energy minimized conformations were generated using the systematic search methodology in Sybyl 6.7. The model not only elucidated the relationship between structure and biological activity but, more importantly, provided useful strategies to modulate CYP2D6 affinity in the aryloxypropanolamine series. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：3816 / 3820

页数：5

共 50 条

[21] CYP2D6 inhibition in patients treated with sertraline
Sproule, BA
Otton, SV
Cheung, SW
Zhong, XH
Romach, MK
Sellers, EM
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1997, 17 (02) : 102 - 106
[22] Dynamics and persistence of CYP2D6 inhibition by paroxetine
Jurica, J.
Zourkova, A.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (04) : 294 - 300
[23] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
Abduljalil, K.
Frank, D.
Gaedigk, A.
Klaassen, T.
Tomalik-Scharte, D.
Jetter, A.
Jaehde, U.
Kirchheiner, J.
Fuhr, U.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
[24] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
Livezey, Mara R.
Briggs, Erran D.
Bolles, Amanda K.
Nagy, Leslie D.
Fujiwara, Rina
Furge, Laura Lowe
XENOBIOTICA, 2014, 44 (04) : 309 - 319
[25] Fuzzy pharmacophore triplets: New descriptors for the construction of QSAR models and application to Cyp2D6 inhibition
Barbosa, Frederique
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232 : 126 - 126
[26] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
Gressier, F.
Verstuyft, C.
Hardy, P.
Becquemont, L.
Corruble, E.
JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
[27] CYP2D6 genotypes in a Japanese population:: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
Nishida, Y
Fukuda, T
Yamamoto, I
Azuma, J
PHARMACOGENETICS, 2000, 10 (06): : 567 - 570
[28] CYP2D6*36 gene arrangements within the CYP2D6 locus:: Association of CYP2D6*36 with poor metabolizer status
Gaedigk, A
Bradford, LD
Alander, SW
Leeder, JS
DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) : 563 - 569
[29] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
F. Gressier
C. Verstuyft
P. Hardy
L. Becquemont
E. Corruble
Journal of Neural Transmission, 2015, 122 : 35 - 42
[30] CYP2D6 multiallelism
Daly, AK
Steen, VM
Fairbrother, KS
Idle, JR
CYTOCHROME P450, PT B, 1996, 272 : 199 - 210

← 1 2 3 4 5 →